Medarex and Boehringer Enter Antibody Development Agreement

Medarex and Boehringer Ingelheim announced an agreement for the development of fully human therapeutic antibodies. Boehringer Ingelheim intends to use Medarex's UltiMAb Human Antibody Development System to generate antibodies to disease targets. Financial terms were not disclosed. Pursuant to the agreement, Boehringer Ingelheim plans to develop and commercialize fully human antibody therapeutics for a variety of diseases, including cancer and inflammatory conditions.

()a href="http://www.medadnews.com/News/index.cfm?articleid=248167" target="_blank">PharmaLive